Company profile: Kinnate Biopharma
1.1 - Company Overview
Company description
- Provider of precision oncology therapeutics for genomically-defined cancers, leveraging structure-based drug discovery and translational research. Pipeline includes exarafenib (KIN-2787), a pan-RAF inhibitor for BRAF/NRAS-driven tumors; KIN-3248 targeting FGFR2/3 alterations in intrahepatic cholangiocarcinoma and urothelial carcinoma; KIN-8741, a selective c-MET inhibitor; and a potentially brain-penetrant CDK4 inhibitor for adult solid tumors.
Products and services
- KIN-8741: A highly selective c-MET inhibitor architected for broad mutational coverage, including acquired resistance mutations, primarily targeting non-small cell lung cancer
- Exarafenib (KIN-2787): A small-molecule pan-RAF inhibitor that targets BRAF and NRAS-driven alterations in advanced solid tumors, produced to address genomically-defined patient populations
- KIN-3248: A small-molecule kinase inhibitor targeting cancer-associated FGFR2 and FGFR3 alterations to treat intrahepatic cholangiocarcinoma and urothelial carcinoma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kinnate Biopharma
Avila Therapeutics
HQ: United States
Website
- Description: Provider of covalent drugs for viral infections, cancers, and autoimmune diseases, designing and developing targeted small-molecule therapies including AVL-181, a hepatitis C virus protease inhibitor; partnered with Sanofi-Aventis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avila Therapeutics company profile →
VeriTeQ
HQ: United States
Website
- Description: Provider of animal and emergency identification solutions, with products used around the world for pet identification via patented, FDA-approved implantable microchips, and for livestock identification and tracking using visual and RFID ear tags.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VeriTeQ company profile →
Rovers
HQ: The Netherlands
Website
- Description: Provider of cancer-screening medical devices, designing, developing, and manufacturing self-sampling and diagnostic tools including Evalyn Brush for at-home HPV screening; Anex Brush for anal cancer screening; Orcellex Brush for oral cancer screening; Viba-Brush and Delphi Screener for cervical cancer self-sampling; and Cervex-Brush for comprehensive cervical cell collection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rovers company profile →
Circio
HQ: Norway
Website
- Description: Provider of active immunotherapy cancer vaccines for post-operation treatments, including TG01, a peptide-based vaccine targeting KRAS/RAS driver mutations in clinical trials for RAS-mutated pancreatic cancer, lung cancer, and multiple myeloma, and circVec, a genetic medicine platform producing multifunctional circular RNA from DNA and viral vectors with enhanced, durable protein expression versus classic mRNA systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Circio company profile →
Sonalasense
HQ: United States
Website
- Description: Provider of noninvasive sonodynamic therapy (SDT) that combines a proprietary intravenous ALA formulation (SONALA-001) with MR-guided focused ultrasound to induce necrosis and apoptosis in gliomas, including glioblastoma multiforme (GBM); conducts clinical trials in solid tumors and advances a pipeline to expand indications across multiple tumor types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sonalasense company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kinnate Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kinnate Biopharma
2.2 - Growth funds investing in similar companies to Kinnate Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kinnate Biopharma
4.2 - Public trading comparable groups for Kinnate Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →